ResearchShould CAR-T Cell Therapy be Considered a Standard of Care for Patients With Refractory Diffuse Large B-Cell Lymphoma in Second Line Treatment?
ResearchOutcomes of Patients With Richter Transformation Who Received No Prior Chemoimmunotherapy for Their CLL
ResearchLeveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies
ResearchSarcopenia and Skeletal Muscle Loss After CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
ResearchEvaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma
ResearchPrognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
ResearchComparison of Axicabtagene Ciloleucel and Tisagenlecleucel Patient CAR-T Cell Products by Single-Cell RNA Sequencing
ResearchFive-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
ResearchThree-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
ResearchBaseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-Cell Lymphoma
ResearchDurable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update